Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV
Metabolic induction by rifampicin accounts for the decrease in plasma exposure of ATV/r. Doubling the ATV/r dosing frequency to BID effectively mitigated this interaction. The plasma exposure of ATV/r mirrored that in PBMCs, suggesting that for these drugs, plasma concentrations provide a reliable reflection of site-of-action exposures.
Authors
- Juan Eduardo Reséndiz‐Galván (ORCID: https://orcid.org/0000-0001-9111-8052)
- Letisha Najjemba (ORCID: https://orcid.org/0000-0002-2264-8292)
- Elin M. Svensson (ORCID: https://orcid.org/0000-0002-0093-6445)
- Amedeo De Nicolò (ORCID: https://orcid.org/0000-0002-5973-9948)
- Allan Kengo (ORCID: https://orcid.org/0009-0000-5084-4314)
- Shakir Atoyebi (ORCID: https://orcid.org/0000-0002-1393-3753)
- Lubbe Wiesner (ORCID: https://orcid.org/0000-0002-9070-8699)
- Paolo Denti (ORCID: https://orcid.org/0000-0001-7494-079X)
- Antonio D’Avolio (ORCID: https://orcid.org/0000-0002-1321-4126)
- Catriona John Waitt (ORCID: https://orcid.org/0000-0003-0134-5855)
- Henry Mugerwa (ORCID: https://orcid.org/0000-0002-9578-5781)
Institutions
- Uppsala University (SE)
- Radboud University Nijmegen (NL)
- University of Liverpool (GB)
- University of Cape Town (ZA)
- Radboud University Medical Center (NL)
- Liverpool Women's Hospital (GB)
- Infectious Diseases Institute (UG)
- Joint Clinical Research Centre (UG)
- University of Turin (IT)
- Makerere University (UG)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1002/bcp.70195
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission
- University of Cape Town
- European and Developing Countries Clinical Trials Partnership